Fortune Business Insights values the worldwide preeclampsia diagnostics market at roughly $1.13 billion for 2025, with expectations that it will climb to about $1.15 billion in 2026 and reach close to $1.46 billion by 2034. This works out to a compound annual growth rate near 3.04% across the 2026–2034 forecast window. North America currently leads all regions, accounting for well over a third of global revenue in 2025.
Preeclampsia is a pregnancy-related hypertensive disorder marked by high blood pressure combined with elevated protein levels in urine. Left undiagnosed, it can progress toward preterm delivery, organ failure, seizures, or even maternal death, making early detection a genuine clinical priority rather than a routine screening formality.
Growth Drivers
Several forces are pushing this market forward. The underlying prevalence of preeclampsia continues to climb, particularly in developing nations, which naturally expands the pool of women who need testing. Diagnostic companies are also racing to commercialize biomarker-based blood tests capable of flagging the condition earlier than traditional blood-pressure and urine checks alone.
Regulatory momentum has reinforced this trend. Health authorities in several countries have cleared or endorsed dedicated preeclampsia assays in recent years, and device makers have responded with steady product launches and strategic partnerships aimed at bringing point-of-care testing closer to patients. Reducing unnecessary hospital admissions through earlier, more accurate screening is a recurring theme across these initiatives.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/preeclampsia-diagnostics-market-101519
Market Restraints
Despite this progress, limited public awareness remains a real obstacle, especially in lower-income regions. Many pregnant women only recognize the danger signs of the disorder once symptoms have already advanced, by which point treatment options narrow considerably. This gap in understanding, paired with uneven access to advanced testing infrastructure, continues to cap adoption in parts of the world where the disease burden is actually highest.
Segmentation Insights
By test type, blood-based diagnostics dominate the landscape, expected to represent roughly 92% of the market in 2026. Their appeal lies in the ability to detect specific biomarkers with strong accuracy, prompting healthcare systems to lean on them over older methods. Urine analysis retains a meaningful role too, valued for being inexpensive, non-invasive, and easy to administer, particularly in resource-constrained settings.
By product, consumables such as reagents and testing kits are projected to hold close to 89% share in 2026, reflecting how recurring biomarker testing drives repeat purchases far more than one-time instrument sales. Instruments still see healthy growth as diagnostic centers expand their equipment base.
By end-user, diagnostic centers are expected to lead with roughly 56% share in 2026, benefiting from their focus on specialized early and late-onset preeclampsia screening. Hospitals remain a significant secondary channel, supported by rising admission volumes among affected patients in developing healthcare markets.
Regional Dynamics
North America's leading position stems from strong healthcare spending and quick uptake of newer diagnostic technologies, with the U.S. market alone approaching roughly $0.4 billion in 2026. Europe follows, buoyed by regulatory approvals and growing clinical awareness, while Asia Pacific is gaining ground quickly thanks to high birth rates and expanding maternal health initiatives, with China, Japan, and India all contributing sizable individual markets. Latin America and the Middle East & Africa remain smaller contributors overall, constrained by comparatively lower healthcare spending, though both are still expected to see gradual expansion.
Competitive Landscape
F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and DRG Instruments GmbH are identified as the market's leading players, distinguished by broad product portfolios and established brand recognition. Additional participants shaping the competitive field include Thermo Fisher Scientific, Diabetomics, Metabolomic Diagnostics, Sera Prognostics, Siemens Healthineers, and Bayer.
Recent industry activity underscores how competitive this space has become: LabCorp introduced an FDA-cleared blood test for severe preeclampsia risk assessment in January 2024, while earlier moves included Thermo Fisher's 2023 FDA-approved predictive blood test and NHS England's 2019 approval of Roche's immunoassay products under an innovation payment scheme. These developments point to an industry where regulatory clearance and biomarker innovation are the primary competitive battlegrounds.
Outlook
With a moderate but steady CAGR of roughly 3.04% projected through 2034, the preeclampsia diagnostics market appears set for measured, sustainable expansion rather than explosive growth. Continued biomarker research, wider regulatory acceptance of blood-based screening, and slowly improving awareness in underserved regions are likely to remain the central themes shaping the industry's trajectory over the coming decade.